TY - JOUR
T1 - Effect of calcium channel blockers on the sensitivity of preoperative 99mTc-MIBI SPECT for hyperparathyroidism
AU - Friedman, Kent
AU - Somervell, Helina
AU - Patel, Pavni
AU - Melton, Genevieve B.
AU - Garrett-Mayer, Elizabeth
AU - Dackiw, Alan P.B.
AU - Civelek, A. Cahid
AU - Zeiger, Martha A.
PY - 2004/12/1
Y1 - 2004/12/1
N2 - Technetium 99m (99mTc)-methoxyisobutylisonitrile (MIBI) single photon emission computed tomography (SPECT) is frequently used in the evaluation of patients with hyperparathyroidism. Calcium channel blockers (CACBs) may affect 99mTc-MIBI uptake by parathyroid cells. This study examines the effect of CACB therapy on the sensitivity of 99mTc-MIBI SPECT localization for hyperparathyroidism. Two hundred fifty-three operated patients with hyperparathyroidism were retrospectively reviewed. The potential effect of CACB therapy on 99mTc-MIBI scan sensitivity was examined by using logistic regression analysis. Possible confounding factors were considered. Among 235 patients, those with multiple endocrine neoplasia, type I (MEN-I), MEN-IIA, 4-gland hyperplasia, secondary hyperparathyroidism, and tertiary hyperparathyroidism exhibited no difference associated with CACB use. Of the remaining 198 patients with primary hyperparathyroidism, 7/30 (23%) with negative 99mTc-MIBI SPECT scans compared to 24/168 (14%) with positive scans used CACBs. After correcting for age, gender and gland weight, the odds ratio (OR) for a negative study in patients taking CACBs was 2.88 (95% CI, 1.03-8.10; P=. 045). Atherosclerosis, hypertension, diabetes mellitus, preoperative calcium and parathyroid hormone levels, and thyroid hormone use were not confounding factors. CACB therapy reduces the sensitivity of 99mTc-MIBI parathyroid SPECT in patients with primary hyperparathyroidism. Further studies are required to determine the potential reversibility of this effect with termination of CACB therapy.
AB - Technetium 99m (99mTc)-methoxyisobutylisonitrile (MIBI) single photon emission computed tomography (SPECT) is frequently used in the evaluation of patients with hyperparathyroidism. Calcium channel blockers (CACBs) may affect 99mTc-MIBI uptake by parathyroid cells. This study examines the effect of CACB therapy on the sensitivity of 99mTc-MIBI SPECT localization for hyperparathyroidism. Two hundred fifty-three operated patients with hyperparathyroidism were retrospectively reviewed. The potential effect of CACB therapy on 99mTc-MIBI scan sensitivity was examined by using logistic regression analysis. Possible confounding factors were considered. Among 235 patients, those with multiple endocrine neoplasia, type I (MEN-I), MEN-IIA, 4-gland hyperplasia, secondary hyperparathyroidism, and tertiary hyperparathyroidism exhibited no difference associated with CACB use. Of the remaining 198 patients with primary hyperparathyroidism, 7/30 (23%) with negative 99mTc-MIBI SPECT scans compared to 24/168 (14%) with positive scans used CACBs. After correcting for age, gender and gland weight, the odds ratio (OR) for a negative study in patients taking CACBs was 2.88 (95% CI, 1.03-8.10; P=. 045). Atherosclerosis, hypertension, diabetes mellitus, preoperative calcium and parathyroid hormone levels, and thyroid hormone use were not confounding factors. CACB therapy reduces the sensitivity of 99mTc-MIBI parathyroid SPECT in patients with primary hyperparathyroidism. Further studies are required to determine the potential reversibility of this effect with termination of CACB therapy.
UR - http://www.scopus.com/inward/record.url?scp=10644242813&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10644242813&partnerID=8YFLogxK
U2 - 10.1016/j.surg.2004.06.047
DO - 10.1016/j.surg.2004.06.047
M3 - Article
C2 - 15657576
AN - SCOPUS:10644242813
SN - 0039-6060
VL - 136
SP - 1199
EP - 1204
JO - Surgery
JF - Surgery
IS - 6
ER -
